CAR-T ther­a­py has rev­o­lu­tion­ized blood can­cer treat­ment, par­tic­u­lar­ly in mul­ti­ple myelo­ma. But an on­go­ing con­cern re­mains: If pa­tients’ can­cers progress af­ter re­ceiv­ing CAR-T, what oth­er...

In­hi­brx Bio­sciences says its lat­est mid-stage re­sults show the po­ten­tial of its OX40 ag­o­nist in im­muno­genic can­cers — but al­so its prospects in com­bi­na­tion with...

Moon­walk Bio­sciences is head­ing to the clin­ic with an obe­si­ty pro­gram and has raised $70 mil­lion for that goal, lean­ing in­to a shift in its...

Plus news about Struc­ture Ther­a­peu­tics, Clover­leaf Bio and Wind­ward Bio.

FDA fi­nal­izes Kraza­ti with­draw­al: Reg­u­la­tors of­fi­cial­ly fi­nal­izedthe drug’s with­draw­al in sec­ond-line col­orec­tal can­cer last...

In the wake of its high-pro­file set­back in heart dis­ease late last week, No­var­tis re­al­ly need­ed a win.

It didn’t get one.

The Swiss phar­ma...